Epilepsy Clinical Articles & Analysis: Older
10 news found
The Company is focused on treating neurological conditions, such as epilepsy, anxiety, depression, and Post Traumatic Stress Disorder "PTSD", including addiction. ...
Neeka Health Is led by a team of proven healthcare innovators with expertise in clinical research and clinical trials for neurological disorders and pain, Will be a significant commercial arm (former professional athletes, their families, veterans and, first responders) for CanaQuest, Spent $9.2 million on their decentralized Clinical ...
Flowonix Medical Inc. of New Jersey, and Colorado-based Cerebral Therapeutics, announced today the first patients implanted with the Prometra II Programmable Infusion System in the Australian Direct Drug Administration for Refractory Epilepsy (ADDRESS) clinical trial at St. Vincent's Hospital, Melbourne, Australia. The jointly developed therapy features a ...
Pharmaceutical: We are perfecting our CQ-001 Drug Candidate (CBD based IP formula) delivery system for Epilepsy in readiness for another Clinical Study for efficacy at the Ontario Brain Institute “OBI”……targeting September. Our first Clinical Study at OBI already achieved a 20% reduction in seizures……..we ...
CIRM grant awarded to accelerate clinical trial of NRTX-1001, a promising regenerative neuronal cell therapy in adults with drug-resistant seizures NRTX-1001 is the first human cell therapy candidate to enter clinical investigation for the treatment of epilepsy Neurona Therapeutics, a clinical-stage biotherapeutics company ...
He previously served as senior medical director at GSK, and as head of neurology clinical research at Sunovion Pharmaceuticals. Prior to working in the pharmaceutical industry, he was in clinical practice as a neurologist at the Barrow Neurological Institute in Arizona for 10 years, where he was director of the epilepsy program. ...
Data from IND-enabling studies show accurate delivery, targeted biodistribution, favorable safety profile, durable suppression of seizures and reduction in disease pathology A first-in-human Phase 1/2 clinical trial of NRTX-1001 in people with drug-resistant mesial temporal lobe epilepsy has been initiated and will begin recruiting soon Neurona ...
Food and Drug Administration (FDA) of its Investigational New Drug (IND) application to initiate its first-in-human Phase 1/2 clinical trial evaluating the safety and efficacy of NRTX-1001 in patients with drug-resistant mesial temporal lobe epilepsy (MTLE). ...
Belgian startup, epihunter, introduces automated video functionality to their CE-marked seizure detection app - a breakthrough for children and adults with epilepsy, their families and doctors. “Including video in epileptic seizure detection has the potential to change the way neurologists and epileptologists assess and document seizure frequency and the effect of ...
“Including video in epileptic seizure detection has the potential to change the way neurologists and epileptologists assess and document seizure frequency and the effect of therapy,” says Dr Sándor Beniczky, Head of Clinical Neurophysiology at the Danish Epilepsy Centre. It is estimated that 1 in 100 people have epilepsy, and ...